<DOC>
	<DOC>NCT01060878</DOC>
	<brief_summary>A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be safe and well tolerated in this study and demonstrate therapeutic benefit in this patient population.</brief_summary>
	<brief_title>Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>confirmed diagnosis of earlystage idiopathic PD within the 2 years prior to screening subjects who are not currently receiving any PD treatment female of childbearing potential history of neurosurgical procedures for PD history of severe psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Early-stage</keyword>
</DOC>